google-site-verification=8uoYEkHPBfwioBbYA4utAsd7-39C4VHNUKlfRmSQA1E

SCOT-MED WILL DO ALL OF THE RESEARCH!

We're Small Enough To Be Agile But Large Enough To Deliver. A credit card is NOT required to register.

In order to protect confidential pricing, we require a registration from your Goverment/First Responders address.

 

Respiratory Test Kit OSOM Flu A + B / SARS-CoV-2 Combo 25 Tests

Log in for pricing

SKU:
SCM114540
Weight:
3.00 LBS
Shipping:
Calculated at Checkout

Product Description

Respiratory Test Kit OSOM Flu A + B / SARS-CoV-2 Combo 25 Tests

Features
  • The OSOM Flu SARS-CoV-2 Combo Test is under FDA Emergency Use Authorization (EUA) only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
  • The OSOM® Flu SARS-CoV-2 Combo Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 by their healthcare provider within the first four (4) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
  • This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Results are for the simultaneous in vitro detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus protein antigen, but does not differentiate, between SARS-CoV and SARS-CoV-2 viruses and is not intended to detect influenza C antigens
  • Positive results do not rule out bacterial infection or co-infection with other viruses; the agent detected may not be the definitive cause of disease
  • All negative results are presumptive, and should be confirmed with a molecular assay, if necessary, for patient management
  • Negative results do not rule out influenza or SARS-CoV-2 infection, and should not be used as the sole basis for treatment or patient management decisions, including infection control measures such as isolating from others and wearing masks
  • Negative results should be considered in the context of an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with each respiratory infection
  • Rapid: Differentiate between three viral infections (COVID-19, Flu A, & Flu B) in only 10 minutes at the point-of-care